Gossamer Bio of San Diego closed a $230 million Series B round that was led by Beijing-based Hillhouse Capital. In January, Gossamer announced a $100 million initial capital raise. The company is developing immunology-based therapeutics for autoimmune, allergy/inflammation and immuno-oncology indications. The company has four products in development, three of them in clinical trials. It said it planned to use the capital for clinical trials of its early and late-stage candidates, along with more in-licensings. More details....
Share this with colleagues:
Original Article: Gossamer Bio Closes $230 Million Series B Led by Beijing's Hillhouse